Logo

American Heart Association

  20
  0


Final ID: Mo4169

Isolated Tricuspid Replacement versus Repair among Medicare Beneficiaries

Abstract Body (Do not enter title and authors here): Background: Evidence is limited regarding mid-term outcomes following isolated tricuspid operations for tricuspid regurgitation at the population level.
Objective: This study aimed to compare the mid-term outcomes following isolated tricuspid valve replacement versus repair using contemporary data.
Methods: We analyzed the national data on Medicare beneficiaries aged ≥65 who underwent isolated tricuspid valve replacement or repair between January 2016 and December 2020. The primary outcome was mid-term (up to 3 years) all-cause mortality. The secondary outcomes included mid-term major adverse cardiovascular events (MACE) and heart failure hospitalizations, as well as in-hospital permanent pacemaker implantation rates. MACE comprised all-cause mortality, heart failure hospitalization, stroke, and tricuspid reoperations. A propensity score-matching analysis was conducted to compare the two groups.
Results: A total of 1,693 patients were included (replacement= 655 patients, repair= 1,038 patients). In the matched cohort (597 patients in each group), the overall mortality and MACE were 40% and 47% at 3 years, respectively. Tricuspid valve replacement was associated with similar all-cause mortality in comparison to repair (adjusted hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.95-1.39; P=0.15). Similarly, the rates of MACE and heart failure hospitalizations were similar (adjusted HR, 1.10; 95% CI, 0.93-1.32, P=0.27; subdistribution HR, 1.07, 95% CI, 0.75-1.54, P=0.69, respectively) between these two procedures. Patients undergoing replacement required permanent pacemaker implantations more frequently (25.4% vs. 12.4%; P<0.001).
Conclusions: Isolated surgical tricuspid valve replacement was associated with similar clinical outcomes compared to repair, except for permanent pacemaker implantation rates. The overall high mid-term mortality and morbidity with either treatment highlight the need for better options and further research to optimize the indication and timing of intervention.
  • Shimoda, Tomonari  ( University of Tsukuba Hospital , Tsukuba City, Ibaraki , Japan )
  • Kuno, Toshiki  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Tsugawa, Yusuke  ( David Geffen School of Medicine at UCLA , Los Angeles , California , United States )
  • Ueyama, Hiroki  ( Emory University School of Medicine , Atlanta , Georgia , United States )
  • Miyamoto, Yoshihisa  ( University of Tokyo , Tokyo , Tokyo , Japan )
  • Watanabe, Atsuyuki  ( Mount Sinai Morningside and West , New York , New York , United States )
  • Gotanda, Hiroshi  ( Cedars-Sinai Medical Center , Los Angeles , California , United States )
  • Elmariah, Sammy  ( Univ California, San Francisco , San Francisco , California , United States )
  • Yokoyama, Yujiro  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Fukuhara, Shinichi  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Kaneko, Tsuyoshi  ( Washington University in St. Louis , St. Louis , Missouri , United States )
  • Author Disclosures:
    Tomonari Shimoda: DO NOT have relevant financial relationships | Toshiki Kuno: DO NOT have relevant financial relationships | Yusuke Tsugawa: DO NOT have relevant financial relationships | Hiroki Ueyama: DO NOT have relevant financial relationships | Yoshihisa Miyamoto: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):DeSC Healthcare:Active (exists now) | Atsuyuki Watanabe: DO NOT have relevant financial relationships | Hiroshi Gotanda: DO NOT have relevant financial relationships | Sammy Elmariah: DO have relevant financial relationships ; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:Edwards Lifesciences:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) | Yujiro Yokoyama: DO NOT have relevant financial relationships | Shinichi Fukuhara: No Answer | Tsuyoshi Kaneko: DO have relevant financial relationships ; Advisor:Edwards Lifesciences:Active (exists now) ; Advisor:Johnson and Johnson:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Advisor:Abbott:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Advanced Approaches in Valvular Disease: From Biomechanics to Clinical Practice

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
Cryptogenic stroke associated with a double interatrial septum treated with surgical closure

Nabi Michelle, Jeha Jeannine, Walker Jennifer, Mahadevan Vaikom, Rastogi Ujjwal

Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study

Judge Daniel, Masri Ahmad, Obici Laura, Poulsen Steen, Sarswat Nitasha, Shah Keyur, Soman Prem, Cao Xiaofan, Wang Kevin, Pecoraro Maria, Tamby Jean-francois, Gillmore Julian, Katz Leonid, Fox Jonathan, Maurer Mathew, Alexander Kevin, Ambardekar Amrut, Cappelli Francesco, Fontana Marianna, Garcia-pavia Pablo, Grogan Martha, Hanna Mazen

More abstracts from these authors:
Salvaging Success: Navigating Next Steps After Initial SAVR or TAVR Failure in Young Patients

Kaneko Tsuyoshi, Fukuhara Shinichi, Nguyen Tom

Transcatheter versus Surgical Tricuspid Repair among Medicare Beneficiaries: One-Year Results

Shimoda Tomonari, Ueyama Hiroki, Miyamoto Yoshihisa, Watanabe Atsuyuki, Gotanda Hiroshi, Tsugawa Yusuke, Kuno Toshiki

You have to be authorized to contact abstract author. Please, Login
Not Available